Tags

Type your tag names separated by a space and hit enter

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].
Nervenarzt 2004; 75(10):1022-6N

Abstract

Based on patient reports, animal data, and in vitro experiments, evidence has emerged indicating a positive effect of cannabinoids as symptomatic treatment of spasticity and pain in multiple sclerosis. The recently published CAMS study was the first multicenter, randomized, placebo-controlled phase III trial to examine the efficacy of cannabinoids on symptoms related to MS. There was no treatment effect of cannabinoids on the primary outcome measure, a difference in the reduction of spasticity as assessed by the so-called Ashworth score. In contrast, significant effects on patient-reported spasticity and pain were documented. A major problem of the study was a high degree of patient unmasking in the active treatment group. In this review, the results of the CAMS study are discussed in the context of previous trials, the putative mechanism of action of cannabinoids and their adverse event profile.

Authors+Show Affiliations

Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf. oliver.neuhaus@uni-duesseldorf.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

15156287

Citation

Neuhaus, Oliver, et al. "[Cannabinoids in Multiple Sclerosis. Opportunity or Hazard?]." Der Nervenarzt, vol. 75, no. 10, 2004, pp. 1022-6.
Neuhaus O, Kieseier BC, Klimke A, et al. [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. Nervenarzt. 2004;75(10):1022-6.
Neuhaus, O., Kieseier, B. C., Klimke, A., Gaebel, W., Hohlfeld, R., & Hartung, H. P. (2004). [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. Der Nervenarzt, 75(10), pp. 1022-6.
Neuhaus O, et al. [Cannabinoids in Multiple Sclerosis. Opportunity or Hazard?]. Nervenarzt. 2004;75(10):1022-6. PubMed PMID: 15156287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. AU - Neuhaus,Oliver, AU - Kieseier,Bernd C, AU - Klimke,Ansgar, AU - Gaebel,Wolfgang, AU - Hohlfeld,Reinhard, AU - Hartung,Hans-Peter, PY - 2004/5/25/pubmed PY - 2004/12/22/medline PY - 2004/5/25/entrez SP - 1022 EP - 6 JF - Der Nervenarzt JO - Nervenarzt VL - 75 IS - 10 N2 - Based on patient reports, animal data, and in vitro experiments, evidence has emerged indicating a positive effect of cannabinoids as symptomatic treatment of spasticity and pain in multiple sclerosis. The recently published CAMS study was the first multicenter, randomized, placebo-controlled phase III trial to examine the efficacy of cannabinoids on symptoms related to MS. There was no treatment effect of cannabinoids on the primary outcome measure, a difference in the reduction of spasticity as assessed by the so-called Ashworth score. In contrast, significant effects on patient-reported spasticity and pain were documented. A major problem of the study was a high degree of patient unmasking in the active treatment group. In this review, the results of the CAMS study are discussed in the context of previous trials, the putative mechanism of action of cannabinoids and their adverse event profile. SN - 0028-2804 UR - https://www.unboundmedicine.com/medline/citation/15156287/[Cannabinoids_in_multiple_sclerosis__Opportunity_or_hazard]_ L2 - https://dx.doi.org/10.1007/s00115-004-1738-z DB - PRIME DP - Unbound Medicine ER -